Drug intelligence / Profile preview

Lodivikar

Development stage: Phase 1
Modality: Small Molecules
Administration: Oral

Overview

Lodivikar is a combination pharmaceutical drug comprising olmesartan and S-amlodipine. Olmesartan is an angiotensin II receptor blocker (ARB) that works by selectively blocking the binding of angiotensin II to its AT1 receptors, leading to vasodilation and a reduction in blood pressure. S-amlodipine is a calcium channel blocker (CCB) that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle cells, thereby causing vasodilation and lowering blood pressure. This combination is primarily used for the treatment of hypertension and angina.

Brand names: Lodivikar
Other names: olmesartan medoxomil/S-amlodipineolmesartan/S-amlodipineolmesartan medoxomil/levamlodipine

Targets

LTCC (Voltage-gated calcium channel (L-type))AGTR1 (Angiotensin II Type-1 receptor)

Beyond the preview

Go deeper on Lodivikar.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lodivikar.

Explore the full profile